Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-Thrombomodulin fusion with endogenous cofactor

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Greineder, Colin F ^a   Chacko, Ann Marie ^a,b   Zaytsev, Sergei ^a   Zern, Blaine J ^a   Carnemolla, Ronald ^a   Hood, Elizabeth D ^a   Han, Jingyan ^a,d   Ding, Bi Sen ^a,c   Esmon, Charles T ^c   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LUNG INJURY; ANIMALS; ANTIGENS, CD; ANTIGENS, CD31; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOCONJUGATES; INTERCELLULAR ADHESION MOLECULE-1; INTERCELLULAR JUNCTIONS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; PROTEIN C; RECEPTORS, CELL SURFACE; SINGLE-CHAIN ANTIBODIES; THROMBOMODULIN;

EID: 84893575812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080110     Document Type: Article

References (54)

1. Pober JS, Sessa WC (2007) Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology 7: 803-815. doi:10.1038/nri2171. (Pubitemid 47480307)
2. Aird WC (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101: 3765-3777. doi:10.1182/blood-2002-06- 1887.
3. Finigan JH (2009) The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc Res 77: 35-38. doi:10.1016/j.mvr.2008. 09.002.
4. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, et al. (2008) Post-Cardiac Arrest Syndrome Epidemiology, Pathophysiology, Treatment, and Prognostication. Circulation 118: 2452-2483. doi:10.1161/CIRCULATIONAHA.108. 190652.
5. Muzykantov VR (2005) Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opinion on Drug Delivery 2: 909-926. doi:10.1517/17425247.2.5.909.
6. Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264: 4743-4746.
7. Esmon CT (2001) The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 5: S7-12.
8. Wouwer MV de, Collen D, Conway EM (2004) Thrombomodulin-Protein C-EPCR System Integrated to Regulate Coagulation and Inflammation. Arterioscler Thromb Vasc Biol 24: 1374-1383. doi:10.1161/01.ATV.0000134298.25489.92.
9. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, et al. (2001) Characterization of a Mouse Model for Thrombomodulin Deficiency. Arterioscler Thromb Vasc Biol 21: 1531-1537. doi:10.1161/hq0901.094496. (Pubitemid 34219820)
10. Nawroth PP, Handley DA, Esmon CT, Stern DM (1986) Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A 83: 3460-3464. (Pubitemid 16051992)
11. Moore KL, Esmon CT, Esmon NL (1989) Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 73: 159-165. (Pubitemid 19040970)
12. MacGregor IR, Perrie AM, Donnelly SC, Haslett C (1997) Modulation of human endothelial thrombomodulin by neutrophils and their release products. Am J Respir Crit Care Med 155: 47-52. (Pubitemid 27053140)
13. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, et al. (1992) Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 90: 2565-2573. doi:10.1172/JCI116151. (Pubitemid 23010079)
14. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408-416. doi:10.1056/NEJM200108093450603. (Pubitemid 32747604)
15. Lin S-M, Wang Y-M, Lin H-C, Lee K-Y, Huang C-D, et al. (2008) Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 36: 683-689. doi:10.1097/CCM. 0B013E31816537D8.
16. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT (2001) Down-Regulation of Endothelial Expression of Endothelial Cell Protein C Receptor and Thrombomodulin in Coronary Atherosclerosis. Am J Pathol 159: 797-802. (Pubitemid 32847169)
17. Sido B, Datsis K, Mehrabi A, Kraus T, Klar E, et al. (1995) Soluble thrombomodulin - a marker of reperfusion injury after orthotopic liver transplantation. Transplantation 60: 462-466.
18. Adrie C, Monchi M, Laurent I, Um S, Yan SB, et al. (2005) Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest: implication of the protein C anticoagulant pathway. J Am Coll Cardiol 46: 21-28. doi:10.1016/j.jacc.2005.03.046. (Pubitemid 40905124)
19. Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, et al. (1999) Local Overexpression of Thrombomodulin for In Vivo Prevention of Arterial Thrombosis in a Rabbit Model. Circulation Research 84: 84-92. doi:10.1161/01.RES.84.1.84. (Pubitemid 29074883)
20. Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, et al. (2002) Early Loss of Thrombomodulin Expression Impairs Vein Graft Thromboresistance Implications for Vein Graft Failure. Circulation Research 90: 205-212. doi:10.1161/hh0202.105097. (Pubitemid 34627090)
21. Tabuchi N, Shichiri M, Shibamiya A, Koyama T, Nakazawa F, et al. (2004) Non-viral in vivo thrombomodulin gene transfer prevents early loss of thromboresistance of grafted veins. Eur J Cardiothorac Surg 26: 995-1001. doi:10.1016/j.ejcts.2004.07.028. (Pubitemid 39433885)
22. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709. doi:10.1056/NEJM200103083441001. (Pubitemid 32204987)
23. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, et al. (2008) Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. Am J Respir Crit Care Med 178: 618-623. doi:10.1164/rccm.200803-419OC.
24. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, et al. (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31-41. doi:10.1111/j.1538-7836. 2006.02267.x. (Pubitemid 44921064)
25. Gentry CA, Gross KB, Sud B, Drevets DA (2009) Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 37: 19-25. doi:10.1097/CCM. 0b013e318192843b.
26. Ding B-S, Hong N, Christofidou-Solomidou M, Gottstein C, Albelda SM, et al. (2009) Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 180: 247-256. doi:10.1164/rccm.200809-1433OC.
27. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 93: 10212-10216. (Pubitemid 26314601)
28. Feistritzer C, Riewald M (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184. doi:10.1182/blood-2004-10-3985.
29. Teasdale MS, Bird CH, Bird P (1994) Internalization of the anticoagulant thrombomodulin is constitutive and does not require a signal in the cytoplasmic domain. Immunol Cell Biol 72: 480-488. doi:10.1038/icb.1994.72.
30. Bae J-S, Yang L, Rezaie AR (2007) Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. PNAS 104: 2867-2872. doi:10.1073/pnas.0611493104. (Pubitemid 46327971)
31. Albelda SM, Muller WA, Buck CA, Newman PJ (1991) Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 114: 1059-1068. doi:10.1083/jcb.114.5.1059. (Pubitemid 21909867)
32. Newman PJ (1997) The biology of PECAM-1. J Clin Invest 99: 3-8. doi:10.1172/JCI119129.
33. Van Buul JD, van Rijssel J, van Alphen FPJ, Hoogenboezem M, Tol S, et al. (2010) Inside-Out Regulation of ICAM-1 Dynamics in TNF-α-Activated Endothelium. PLoS ONE 5: e11336. doi:10.1371/journal.pone.0011336.
34. Dübel S, Breitling F, Fuchs P, Zewe M, Gotter S, et al. (1994) Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. Journal of Immunological Methods 175: 89-95. doi:10.1016/0022-1759(94)90334-4. (Pubitemid 24305234)
35. Crowe JS, Smith MA, Cooper HJ (1989) Nucleotide sequence of Y3-Ag 1.2.3. rat myeloma immunoglobulin kappa chain cDNA. Nucleic Acids Res 17: 7992. (Pubitemid 19251965)
36. Fukudome K, Esmon CT (1995) Molecular Cloning and Expression of Murine and Bovine Endothelial Cell Protein C/Activated Protein C Receptor (EPCR) The Structural and Functional Conservation in Human, Bovine, and Murine EPCR. J Biol Chem 270: 5571-5577. doi:10.1074/jbc.270.10.5571.
37. Chacko A-M, Nayak M, Greineder CF, DeLisser HM, Muzykantov VR (2012) Collaborative Enhancement of Antibody Binding to Distinct PECAM-1 Epitopes Modulates Endothelial Targeting. PLoS ONE 7: e34958. doi:10.1371/journal.pone. 0034958.
38. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, et al. (2005) Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. Journal of Thrombosis and Haemostasis 3: 1351-1359. doi:10.1111/j.1538-7836.2005.01385.x. (Pubitemid 41725187)
39. Newman PJ (1994) The Role of PECAM-1 in Vascular Cell Biologya. Annals of the New York Academy of Sciences 714: 165-174. doi:10.1111/j.1749-6632.1994. tb12041.x.
40. Newby A, Baker A (1999) Targets for gene therapy of vein grafts. [Review] [37 refs]. Current Opinion in Cardiology 14: 489-494.
41. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, et al. (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925. (Pubitemid 17050920)
42. Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, et al. (2011) The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost 9: 1174-1182. doi:10.1111/j.1538- 7836.2011.04269.x.
43. Kowalski PS, Leus NGJ, Scherphof GL, Ruiters MHJ, Kamps JAAM, et al. (2011) Targeted siRNA delivery to diseased microvascular endothelial cells - Cellular and molecular concepts. IUBMB Life 63: 648-658. doi:10.1002/iub.487.
44. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C (2008) PLGA nanoparticle - peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem 19: 145-152. doi:10.1021/bc700227z. (Pubitemid 351213845)
45. Simone E, Ding B-S, Muzykantov V (2009) Targeted delivery of therapeutics to endothelium. Cell Tissue Res 335: 283-300. doi:10.1007/s00441-008-0676-7.
46. Chrastina A, Valadon P, Massey KA, Schnitzer JE (2010) Lung vascular targeting using antibody to aminopeptidase P: CT-SPECT imaging, biodistribution and pharmacokinetic analysis. J Vasc Res 47: 531-543. doi:10.1159/000313880.
47. Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, et al. (2001) Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280: L1335-1347.
48. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, et al. (2000) Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis. Cancer Res 60: 722-727. (Pubitemid 30094573)
49. Torchilin VP (2006) Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8: 343-375. doi:10.1146/annurev.bioeng.8.061505.095735.
50. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, et al. (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant-activated protein C. J Exp Med 204: 2439-2448. doi:10.1084/jem.20070404. (Pubitemid 47529328)
51. Staunton DE, Dustin ML, Erickson HP, Springer TA (1990) The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 61: 243-254. doi:10.1016/0092-8674(90)90805-O.
52. Christofidou-Solomidou M, Kennel S, Scherpereel A, Wiewrodt R, Solomides CC, et al. (2002) Vascular Immunotargeting of Glucose Oxidase to the Endothelial Antigens Induces Distinct Forms of Oxidant Acute Lung Injury. Am J Pathol 160: 1155-1169.
53. Muro S, Koval M, Muzykantov V (2004) Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2: 281-299. (Pubitemid 38855034)
54. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, et al. (2003) A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 116: 1599-1609. doi:10.1242/jcs.00367. (Pubitemid 36527505)